Enhertu Injection 1vial x 100mg(,DS-8201) (fam-trastuzumab deruxtecan-nxki)

Reference priceBRL R$3,412.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Enhertu
Manufacturer	Daiichi Sankyo Co.Ltd.
Prescription required	Yes

Description

Enhertu Injection 1vial x 100mg(,DS-8201) (fam-trastuzumab deruxtecan-nxki) is a medicine catalog record in the MediPriceHub database. Active ingredient: fam-trastuzumab deruxtecan-nxki. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Daiichi Sankyo Co.Ltd.. Therapeutic category: Medicine Library > Oncology Medicines > Unknown cancer drug. Pack information: 100. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for: HER2-Positive Early Breast Cancer HER2-Positive Metastatic Breast Cancer HER2-Low and HER2-Ultralow Metastatic Breast Cancer HER2-Mutant Unresectable or Metastatic Non-Small Cell Lung Cancer HER2-Positive Locally Advanced or Metastatic Gastric Cancer HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test followed by a taxane, trastuzumab, and pertuzumab (THP). as adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment. in combination with pertuzumab as first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as determined by an FDA-authorized test. as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or, in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membra

How to Use

Use fam-trastuzumab deruxtecan-nxki under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: fam-trastuzumab deruxtecan-nxki. Pack size: 100. Pack unit: bottle. Manufacturer: Daiichi Sankyo Co.Ltd.. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Unknown cancer drug. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

Esta informação é apenas para referência. Consulte um profissional de saúde antes de usar qualquer medicamento.